Treatment of central nervous system tuberculosis infections and neurological complications of tuberculosis treatment

Current Pharmaceutical Design

Volumn 17, Issue 27, 2011, Pages 2940-2947

  van der Harst, J J ^a   Luijckx, G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adverse neurotoxic effects; Antituberculosis agents; Blood brain barrier; Central nervous system; Corticosteroids; Thalidomide; Tuberculosis; Tuberculous meningitis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CALCIUM; CAPREOMYCIN; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSERINE; DEXAMETHASONE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; IMMUNOMODULATING AGENT; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; MUSCLE RELAXANT AGENT; NEOSTIGMINE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ABSCESS DRAINAGE; AGITATION; ANOREXIA; ANXIETY DISORDER; ARACHNOIDITIS; ARTICLE; ATAXIA; AUTISM; BACTEREMIA; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN PSEUDOTUMOR; BRAIN VENTRICLE PERITONEUM SHUNT; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CEREBROSPINAL FLUID CULTURE; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COHORT ANALYSIS; COMMUNICATING HYDROCEPHALUS; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONSCIOUSNESS DISORDER; CONVULSION; CRANIAL NERVE PARALYSIS; DELIRIUM; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DIZZINESS; DREAM; DROWSINESS; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; EPILEPSY; FEVER; HEADACHE; HEARING IMPAIRMENT; HEARING LOSS; HEMIPARESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCEPHALUS; HYPOMANIA; HYPOPYON; INSOMNIA; INTRACRANIAL TUBERCULOMA; LAMINECTOMY; LIVER TOXICITY; MENINGISM; META ANALYSIS (TOPIC); MOOD DISORDER; MYCOBACTERIUM TUBERCULOSIS; MYOCLONUS; MYOPATHY; NEURITIS; NEUROLOGICAL COMPLICATION; NEUROMUSCULAR BLOCKING; NEUROPATHIC PAIN; NEUROPATHY; NEUROSURGERY; NEW DAILY PERSISTENT HEADACHE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEIC ACID AMPLIFICATION; OPTIC NEURITIS; OSCILLOMETRY; OSCILLOPSIA; OTOTOXICITY; PARANOID PSYCHOSIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PORPHYRIA; PRIORITY JOURNAL; PSYCHOSIS; PYRIDOXINE DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; RETROBULBAR OPTIC NEUROPATHY; SEIZURE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STEREOTACTIC ASPIRATION; STUPOR; SUICIDE; TUBERCULOUS MENINGITIS; TUBERCULOUS SPONDYLITIS; UNSPECIFIED SIDE EFFECT; UVEITIS; VESTIBULAR DISORDER; VOMITING; WEIGHT REDUCTION;

EID: 80053616234     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797470237     Document Type: Article

References (102)

1. Garg RK. Tuberculous meningitis. Acta Neurol Scand 2010; 122(2): 75-90.
2. Cailhol J, Che D, Jarlier V, Decludt B, Robert J. Incidence of tuberculous meningitis in France, 2000: a capture-recapture analysis. Int J Tuberc Lung Dis 2005; 9(7): 803-8.
3. Hooker JA, Muhindi DW, Amayo EO, Mc'ligeyo SO, Bhatt KM, Odhiambo JA. Diagnostic utility of cerebrospinal fluid studies in patients with clinically suspected tuberculous meningitis. Int J Tuberc Lung Dis 2003; 7(8): 787-96.
4. Girgis NI, Sultan Y, Farid Z, et al. Tuberculosis meningitis, Abbassia Fever Hospital-Naval Medical Research Unit No. 3-Cairo, Egypt, from 1976 to 1996. Am J Trop Med Hyg 1998; 58(1): 28-34.
5. Yasar KK, Pehlivanoglu F, Sengoz G. Predictors of mortality in tuberculous meningitis: a multivariate analysis of 160 cases. Int J Tuberc Lung Dis 2010; 14(10): 1330-5.
6. Nguyen LT, Hamilton CD, Xia Q, Stout JE. Mortality before or during treatment among tuberculosis patients in North Carolina, 1993-2003. Int J Tuberc Lung Dis 2011; 15(2): 257-62.
7. Hosoglu S, Ayaz C, Geyik MF, Kokoglu OF, Ceviz A. Tuberculous meningitis in adults: an eleven-year review. Int J Tuberc Lung Dis 1998; 2(7): 553-7.
8. Verdon R, Chevret S, Laissy JP, Wolff M. Tuberculous meningitis in adults: review of 48 cases. Clin Infect Dis 1996; 22(6): 982-8.
9. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20(3 Suppl): 21-35.
10. Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008; 21(2): 243-61, table.
11. Caws M, Thwaites G, Dunstan S, et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008; 4(3): e1000034.
12. Thwaites GE, Tran TH. Tuberculous meningitis: many questions, too few answers. Lancet Neurol 2005; 4(3): 160-70.
13. Be NA, Kim KS, Bishai WR, Jain SK. Pathogenesis of central nervous system tuberculosis. Curr Mol Med 2009; 9(2): 94-9.
14. Kumar R, Pandey CK, Bose N, Sahay S. Tuberculous brain abscess: clinical presentation, pathophysiology and treatment (in children). Childs Nerv Syst 2002; 18(3-4): 118-23.
15. Schirmer P, Renault CA, Holodniy M. Is spinal tuberculosis contagious? Int J Infect Dis 2010; 14(8): e659-66.
16. Jain AK. Tuberculosis of the spine: a fresh look at an old disease. J Bone Joint Surg Br 2010; 92(7): 905-13.
17. Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM. Tuberculosis of the central nervous system in children: a 20-year survey. J Infect 2000; 41(1): 61-8.
18. Marais S, Pepper DJ, Marais BJ, Torok ME. HIV-associated tuberculous meningitis - diagnostic and therapeutic challenges. Tuberculosis (Edinb) 2010; 90(6): 367-74.
19. Thwaites GE, Chau TT, Stepniewska K, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet 2002 26; 360(9342): 1287-92.
20. Marshall G, Blacklok JS, Cameron C, et al. Streptomycin treatment of tuberculous meningitis. The Lancet 1948 17; 251(6503): 581-620.
21. Sutlas PN, Unal A, Forta H, Senol S, Kirbas D. Tuberculous meningitis in adults: review of 61 cases. Infection 2003; 31(6): 387-91.
22. Thwaites G, Chau TT, Mai NT, Drobniewski F, McAdam K, Farrar J. Tuberculous meningitis. J Neurol Neurosurg Psychiatry 2000; 68(3): 289-99.
23. Kennedy DH, Fallon RJ. Tuberculous meningitis. JAMA 1979 19; 241(3): 264-8.
24. Johansen IS, Lundgren B, Tabak F, et al. Improved sensitivity of nucleic acid amplification for rapid diagnosis of tuberculous meningitis. J Clin Microbiol 2004; 42(7): 3036-40.
25. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003 15; 167(4): 603-62.
26. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009; 59(3): 167-87.
27. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008; (1): CD002244.
28. Rutherford P, Shovelton DH, Higgins R, Wise F, Young Y. NICE guideline - tuberculosis. 2006.
29. World Health Organization. Treatment of tuberculosis guidelines. Fourth edition ed. 2010.
30. Nau R, Sorgel F, Eiffert H. Penetration of drugs through the bloodcerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23(4): 858-83.
31. Donald PR, Gent WL, Seifart HI, Lamprecht JH, Parkin DP. Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status. Pediatrics 1992; 89(2): 247-50.
32. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 2010; 90(5): 279-92.
33. Stuart MC, Kouimtzi M, Hill S, World Health Organization. WHO model formulary 2008. 2009.
34. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs 2010 1; 24(8): 655-67.
35. Jenkins P, Emerson PA. Myopathy induced by rifampicin. Br Med J (Clin Res Ed) 1981 11; 283(6284): 105-6.
36. Skolik S, Willermain F, Caspers LE. Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. Ocul Immunol Inflamm 2005; 13(6): 483-5.
37. Ebraert H, Salu P. Toxic uveitis caused by pharmacodynamics interactions of Rifabutin and protease inhibitors: a case report. Bull Soc Belge Ophtalmol 2007; (303): 57-60.
38. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007; (4): CD005159.
39. Jetton J, Gaviria JG, Patterson TF, Johnson DA. Rifabutinassociated uveitis in an immunocompetent individual with Mycobacterium simiae. Can J Ophthalmol 2009; 44(4): 468-9.
40. Ellard GA, Humphries MJ, Gabriel M, Teoh R. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br Med J (Clin Res Ed) 1987 31; 294(6567): 284-5.
41. CARR RE, HENKIND P. Ocular manifestations of ethambutol, Toxic amblyopia after administration of an experimental antituberculous drug. Arch Ophthalmol 1962; 67: 566-71.
42. Kokkada SB, Barthakur R, Natarajan M, Palaian S, Chhetri AK, Mishra P. Ocular side effects of antitubercular drugs - a focus on prevention, early detection and management. Kathmandu Univ Med J (KUMJ) 2005; 3(4): 438-41.
43. Polak BC, Leys M, van Lith GH. Blue-yellow colour vision changes as early symptoms of ethambutol oculotoxicity. Ophthalmologica 1985; 191(4): 223-6.
44. Kaimbo WK, Bifuko ZA, Longo MB, Dralands L, Missotten L. Color vision in 42 Congolese patients with tuberculosis receiving ethambutol treatment. Bull Soc Belge Ophtalmol 2002; (284): 57-61.
45. Srivastava AK, Goel UC, Bajaj S, Singh KJ, Dwivedi NC, Tandon MP. Visual evoked responses in ethambutol induced optic neuritis. J Assoc Physicians India 1997; 45(11): 847-9.
46. Mendez-Echevarria A, Baquero-Artigao F, Garcia-Miguel MJ, Pascual SI, Velazquez R, Del CF. Visual evoked responses in children with tuberculosis treated with ethambutol. Pediatr Infect Dis J 2007; 26(1): 92-3.
47. Lee EJ, Kim SJ, Choung HK, Kim JH, Yu YS. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuroophthalmol 2008; 28(4): 269-77.
48. Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax 1986; 41(10): 737-9.
49. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966; 135(2): 904-9.
50. Whitlock FA. Adverse psychiatric reactions to modern medication. Aust N Z J Psychiatry 1981; 15(2): 87-103.
51. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004; 161(11): 2115-7.
52. Millecamps M, Centeno MV, Berra HH, et al. D-cycloserine reduces neuropathic pain behavior through limbic NMDAmediated circuitry. Pain 2007; 132(1-2): 108-23.
53. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008 15; 63(6): 544-9.
54. Vora A. Terizidone. J Assoc Physicians India 2010; 58: 267-8.
55. Gupta DK. Acceptability of thioamides. II. Prothionamide. J Postgrad Med 1977; 23(4): 181-5.
56. Nishida CR, Ortiz de Montellano PR. Bioactivation of antituberculosis thioamide and thiourea prodrugs by bacterial and mammalian flavin monooxygenases. Chem Biol Interact 2010.
57. Schaaf HS, Victor TC, Venter A, et al. Ethionamide cross-and coresistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13(11): 1355-9.
58. Freiman I, Geefhuysen J. Evaluation of intrathecal therapy with streptomycin and hydrocortisone in tuberculous meningitis. J Pediatr 1970; 76(6): 895-901.
59. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007; 13(1): 119-26.
60. Sikh SS, Sachdev KS. Duration of the neuromuscular blocking action of streptomycin. Br J Anaesth 1965; 37: 158-60.
61. McQuillen MP, Cantor HE, O'Rourke JR. Myasthenic syndrome associated with antibiotics. Arch Neurol 1968; 18(4): 402-15.
62. Foldes FF, Lunn JN, Benz HG. Prolonged respiratory depression caused by drug combinations. Muscle relaxants and intraperitoneal antibiotics as etiologic agents. JAMA 1963 23; 183: 672-3.
63. Magazine R, Pal M, Chogtu B, Nayak V. Capreomycin-induced optic neuritis in a case of multidrug resistant pulmonary tuberculosis. Indian J Pharmacol 2010; 42(4): 247-8.
64. Nelson M, Huggins T, Licorish R, Carroll MA, Catapane EJ. Effects of p-Aminosalicylic acid on the neurotoxicity of manganese on the dopaminergic innervation of the cilia of the lateral cells of the gill of the bivalve mollusc, Crassostrea virginica. Comp Biochem Physiol C Toxicol Pharmacol 2010; 151(2): 264-70.
65. Ky SQ, Deng HS, Xie PY, Hu W. A report of two cases of chronic serious manganese poisoning treated with sodium paraaminosalicylic acid. Br J Ind Med 1992; 49(1): 66-9.
66. Thwaites GE, Bhavnani SM, Thi Hong CT, et al. A randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011.
67. Alffenaar JW, van AR, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49(7): 1080-2.
68. Alffenaar JW, de Vries PM, Luijckx GJ, van SD, van der Werf TS, van AR. Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis. Antimicrob Agents Chemother 2008; 52(6): 2293-5.
69. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46(4): 1022-5.
70. Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000; 45(6): 859-70.
71. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10(6): 605-12.
72. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008; (1): CD004795.
73. INCHEM. Clofazimine. http://www.inchem.org/documents/pims/pharm/clofaz.htm. Date of access: 4-1-2011. Ref Type: Internet Communication
74. Cunningham CA, Friedberg DN, CARR RE. Clofazamine-induced generalized retinal degeneration. Retina 1990; 10(2): 131-4.
75. Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65(4): 775-83.
76. Weiss K, Vanjaka A. An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. Clin Ther 2002; 24(12): 2105-22.
77. FDA. If one would have Vertigo while taking Clarithromycin, who are they, when it happens and how? http://www.ehealthme.com/ds/clarithromycin/vertigo 2011; Date of access: 2-4-2011. Ref Type: Internet Communication
78. Coulston J, Balaratnam N. Irreversible sensorineural hearing loss due to clarithromycin. Postgrad Med J 2005; 81(951): 58-9.
79. Kolkman W, Groeneveld JH, Baur HJ, Verschuur HP. [Ototoxicity induced by clarithromycin]. Ned Tijdschr Geneeskd 2002; 146(37): 1743-5.
80. Erkek N, Senel S, Karacan C. Visual hallucinations possibly associated with clarithromycin administration at therapeutic dosage in two children. Med Princ Pract 2009; 18(4): 332-4.
81. Jimenez P, Navarro-Ruiz A, Sendra P, Martinez-Ramirez M, Garcia-Motos C, Montesinos-Ros A. Hallucinations with therapeutic doses of clarithromycin. Int J Clin Pharmacol Ther 2002; 40(1): 20-2.
82. Ozsoylar G, Sayin A, Bolay H. Clarithromycin monotherapyinduced delirium. J Antimicrob Chemother 2007; 59(2): 331.
83. Bandettini di PM, Anfosso S, Audenino D, Primavera A. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci 2011; 18(3): 313-8.
84. Pijpers E, van Rijswijk RE, Takx-Kohlen B, Schrey G. A clarithromycin-induced myasthenic syndrome. Clin Infect Dis 1996; 22(1): 175-6.
85. Cooper JM, Jones AL. Neuroleptic malignant syndrome or a statin drug reaction? A case report. Clin Neuropharmacol 2009; 32(6): 348-9.
86. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006; 81(10): 1361-7.
87. Tsenova L, Bergtold A, Freedman VH, Young RA, Kaplan G. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci USA 1999 11; 96(10): 5657-62.
88. Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998; 177(6): 1563-72.
89. Schoeman JF, Springer P, van Rensburg AJ, et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004; 19(4): 250-7.
90. Schoeman JF, Andronikou S, Stefan DC, Freeman N, van TR. Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases. J Child Neurol 2010; 25(7): 822-8.
91. Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010; 36 Suppl 2: S24-S32.
92. Schoeman J, Donald P, van ZL, Keet M, Wait J. Tuberculous hydrocephalus: comparison of different treatments with regard to ICP, ventricular size and clinical outcome. Dev Med Child Neurol 1991; 33(5): 396-405.
93. Rajshekhar V. Management of hydrocephalus in patients with tuberculous meningitis. Neurol India 2009; 57(4): 368-74.
94. Lamprecht D, Schoeman J, Donald P, Hartzenberg H. Ventriculoperitoneal shunting in childhood tuberculous meningitis. Br J Neurosurg 2001; 15(2): 119-25.
95. Kemaloglu S, Ozkan U, Bukte Y, Ceviz A, Ozates M. Timing of shunt surgery in childhood tuberculous meningitis with hydrocephalus. Pediatr Neurosurg 2002; 37(4): 194-8.
96. Srikantha U, Morab JV, Sastry S, et al. Outcome of ventriculoperitoneal shunt placement in Grade IV tubercular meningitis with hydrocephalus: a retrospective analysis in 95 patients. Clinical article. J Neurosurg Pediatr 2009; 4(2): 176-83.
97. Palur R, Rajshekhar V, Chandy MJ, Joseph T, Abraham J. Shunt surgery for hydrocephalus in tuberculous meningitis: a long-term follow-up study. J Neurosurg 1991; 74(1): 64-9.
98. Lee TC, Lu K, Yang LC, Huang HY, Liang CL. Transpedicular instrumentation as an adjunct in the treatment of thoracolumbar and lumbar spine tuberculosis with early stage bone destruction. J Neurosurg 1999; 91(2 Suppl): 163-9.
99. Guzey FK, Emel E, Bas NS, et al. Thoracic and lumbar tuberculous spondylitis treated by posterior debridement, graft placement, and instrumentation: a retrospective analysis in 19 cases. J Neurosurg Spine 2005; 3(6): 450-8.
100. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351(17): 1741-51.
101. Girgis NI, Farid Z, Kilpatrick ME, Sultan Y, Mikhail IA. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J 1991; 10(3): 179-83.
102. Thwaites GE, Schoeman JF. Update on tuberculosis of the central nervous system: pathogenesis, diagnosis, and treatment. Clin Chest Med 2009; 30(4): 745-54, ix.